|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.63 USD | -1.46% |
|
-5.89% | +68.48% |
| 12-05 | Cvs Health generates over $474 billion in 2024 U.S. economic impact, supporting communities throughout the United States | RE |
| 12-04 | Bernstein Adjusts CVS Health Price Target to $86 From $77 | MT |
| Capitalization | 96.01B 82.53B 77.31B 72.06B 133B 8,641B 145B 904B 349B 4,081B 360B 353B 14,921B | P/E ratio 2025 * |
152x | P/E ratio 2026 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise value | 154B 132B 124B 116B 214B 13,861B 232B 1,451B 560B 6,546B 578B 566B 23,936B | EV / Sales 2025 * |
0.39x | EV / Sales 2026 * | 0.36x |
| Free-Float |
70.66% | Yield 2025 * |
3.64% | Yield 2026 * | 3.82% |
Last Transcript: CVS Health Corporation
| 1 day | -1.46% | ||
| 1 week | -5.89% | ||
| Current month | -5.89% | ||
| 1 month | -3.72% | ||
| 3 months | +2.51% | ||
| 6 months | +19.90% | ||
| Current year | +68.48% |
| 1 week | 74.14 |  | 81.06 |
| 1 month | 74.14 | | 81.72 |
| Current year | 44.11 | | 85.15 |
| 1 year | 43.56 | | 85.15 |
| 3 years | 43.56 | | 104.83 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 61 | 2024-10-16 |
Prem Shah
PSD | President | 45 | 2024-11-05 |
Brian Newman
DFI | Director of Finance/CFO | 56 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 73 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 72 | 2011-01-19 |
| Director/Board Member | 70 | 2015-03-04 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.92% | 26 M€ | +11.73% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.46% | -5.89% | +33.01% | -25.86% | 96.01B | |
| -0.20% | -4.25% | +52.07% | +106.80% | 111B | |
| -0.60% | +0.82% | +40.48% | +79.26% | 31.16B | |
| +2.20% | +3.89% | -12.84% | +14.91% | 23.43B | |
| -1.18% | -3.87% | +10.00% | +9.31% | 21.42B | |
| -0.91% | -3.53% | +15.13% | +22.56% | 20.3B | |
| -7.00% | -5.43% | +61.95% | +51.18% | 17.98B | |
| -1.01% | -3.15% | +51.19% | +370.85% | 18.46B | |
| +0.21% | -5.15% | +17.87% | +81.44% | 14.44B | |
| +0.07% | -2.93% | -12.40% | +29.29% | 13.36B | |
| Average | -0.99% | -2.86% | +25.65% | +73.97% | 36.76B | |
| Weighted average by Cap. | -0.85% | -3.62% | +34.23% | +60.35% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 399B 343B 321B 299B 553B 35,909B 602B 3,758B 1,451B 16,960B 1,498B 1,466B 62,011B | 418B 360B 337B 314B 580B 37,649B 631B 3,940B 1,521B 17,781B 1,570B 1,537B 65,015B |
| Net income | -206M -177M -166M -154M -285M -18.52B -310M -1.94B -748M -8.75B -772M -756M -31.98B | 7.23B 6.21B 5.82B 5.43B 10.02B 651B 10.9B 68.09B 26.29B 307B 27.13B 26.55B 1,123B |
| Net Debt | 58.01B 49.86B 46.71B 43.54B 80.41B 5,220B 87.47B 546B 211B 2,466B 218B 213B 9,015B | 52.8B 45.38B 42.51B 39.63B 73.19B 4,752B 79.61B 497B 192B 2,244B 198B 194B 8,205B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 75.63 $ | -1.46% | 7,768,387 |
| 25-12-04 | 76.75 $ | +2.33% | 8,872,740 |
| 25-12-03 | 75.00 $ | -3.38% | 8,164,509 |
| 25-12-02 | 77.62 $ | -1.87% | 7,700,857 |
| 25-12-01 | 79.10 $ | -1.57% | 6,754,424 |
Delayed Quote Nyse, December 05, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition